The scientific programme for the EANO-EORTC CNS Metastasis Meeting 2027 is taking shape and it reflects the multidisciplinary approach needed to tackle one of oncology's greatest challenges. Explore the programme and register today:
www.eano.eu/eanomeetings...
#CNSmetastasis2027 @eortc.org

👏Outstanding science across the fields of #NeuroOncology: Congratulations to our #EANO2026 award winners for Best Poster Presentation: P. Watchmaker (Clinical research), A. Tron (Basic research), A. Mathioudaki (Translational research), and S. Nordentoft (Supportive care & quality of life research)!

From ROAM/EORTC 1308 to VIGOR and new glioma research, EORTC abstracts contributed important evidence presented at #EANO2026.

🔗 Read more: https://www.eortc.org/blog/2026/09/28/eortc-presents-new-results-at-eano/

EANO #EORTCbrain

Presented at this year’s #EANO2026 Congress in Rome and simultaneously published in The Lancet.

Thank you to @thelancet.com for the excellent collaboration!

Interesting data from #STERIMGLI at #EANO2026 on #re-irradiation + #durvalumab for recurrent glioblastoma:

➡️ HF-SRT 24 Gy/3 fx
➡️ Primary OS endpoint not met in ITT population (16.1 vs 13.3 months)
➡️ QoL and cognition maintained
➡️ Exploratory analyses suggest a stronger OS in WHO 2021 glioblastoma

Now at #EANO2026 on #radiotherapy in glioblastoma 🧠:

➡️ #FET-PET-informed target volumes were larger than MRI-only volumes
➡️ MRI-based plans showed lower coverage

📄Take-home: MRI-only planning may under-cover disease, but whether this translates into better tumour control still needs to be shown

📢 Just presented at #EANO2026 – and now published in Neuro-Oncology!
The study “Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma: Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06”, presented by Eng-Siew Koh: doi.org/10.1093/neuo...

The final day of the #EANO2026 scientific programme is underway in Rome!
There is still plenty of science, clinical research and exchange ahead as we come together for another day across the #NeuroOncology community.
www.eano.eu/eano2026/pro...
#btsm #BrainTumor #EANO

#EANO2026 continues in #Rome on another beautiful day ☀️

This morning, don’t miss:
➡️selected abstracts sessions 📄
➡️pro/contra debate on chemo-RT for IDH-mutant grade 3 gliomas, from Susan Short and Martin van den Bent 🧠

Looking forward to another full day of science and discussion!
#radiotherapy

Prof. Susan Short made the Pro case for #radiotherapy + chemotherapy in every patient with grade 3 IDH-mutant #glioma.
A great debate around which treatments we can, and should, deliver to this population #EANO2026

Extremely nice to see a large Polish delegation at @EANOassociation #EANO2026 - recently formed Polish Society for Neuro-Oncology is represented well at this year’s meeting! Makes me very happy 😃

Poster session time at #EANO2026!

Don’t miss the opportunity to have engaging discussions with presenters and colleagues 🗣️
Here few posters that caught my attention 👇🏻 Go and check it out yourselves
#RadiationOncology #NeuroOncology

📢 Just presented at #EANO2026 – and now published in Neuro-Oncology! The study “Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma”, presented by first author Tamara Künzle, is now available in Neuro-Oncology.
🔗 doi.org/10.1093/neuo...

📢 Just presented at #EANO2026 – now published in Neuro-Oncology! The study “Potentially Inappropriate Care at the End of Life in Patients with Glioblastoma: A Single-Center Observational Cohort Study”, presented by first author Robin Pieterman, is now available open access.
🔗 doi.org/10.1093/neuo...

Day 2 of the #EANO2026 scientific programme is underway in Rome! Another full day of high-level science, clinical advances & exchange across all disciplines in #NeuroOncology awaits.
📍Don’t miss today’s highlights, presented in comments:
Full programme:
www.eano.eu/eano2026/pro...
#BrainTumor #EANO

At #EANO2026, #EORTC 2227-LEGATO trial is addressing an important question: does adding #reirradiation to lomustine improve outcomes compared with lomustine alone in #glioblastoma?
Hopefully this phase III trial will generate the evidence needed to define the role of reRT at first progression.

Poster session time at #EANO2026! 🧠
If you’re around, don’t miss the #Radiotherapy poster section as well.
Lots of interesting work on RT, from quality assurance, dose, and treatment
#RadiationOncology #NeuroOncology #RTQA #Radiotherapy